Tempest Therapeutics Inc Total Liabilities
Tempest Therapeutics Inc total liabilities. Based on the latest financial reports, Tempest Therapeutics Inc (TPST) has total liabilities worth $10.72 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check how resilient are Tempest Therapeutics Inc's assets to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Tempest Therapeutics Inc (2011–2025)
Total liabilities of Tempest Therapeutics Inc from 2011 to 2025. This chart illustrates how Tempest Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data.
Tempest Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Tempest Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Turbon AG
F:TUR
|
Germany | €15.83 Million |
|
Jenn Feng New Energy Co Ltd
TW:1538
|
Taiwan | NT$127.61 Million |
|
KWESST MICRO SYS.INC.
F:62UA
|
Germany | €4.09 Million |
|
Soligenix Inc.
NASDAQ:SNGX
|
USA | $3.85 Million |
|
Indiana Resources Ltd
AU:IDA
|
Australia | AU$3.34 Million |
|
Bergenbio ASA
OL:BGBIO
|
Norway | Nkr19.75 Million |
|
Caely Holdings Bhd
KLSE:7154
|
Malaysia | RM23.51 Million |
|
Cambium Bio Ltd
AU:CMB
|
Australia | AU$1.46 Million |
Liability Composition Analysis (2011–2025)
This chart breaks down Tempest Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Tempest Therapeutics Inc asset portfolio.
Liquidity & Leverage Metrics
Tempest Therapeutics Inc Total Liabilities Ratios Explained
Tempest Therapeutics Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.38 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -9.84 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.11 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Tempest Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Tempest Therapeutics Inc (2011–2025)
The table below shows the annual total liabilities of Tempest Therapeutics Inc from 2011 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $10.26 Million | -54.11% |
| 2024-12-31 | $22.36 Million | -9.96% |
| 2023-12-31 | $24.84 Million | -11.23% |
| 2022-12-31 | $27.98 Million | -24.63% |
| 2021-12-31 | $37.12 Million | -59.50% |
| 2020-12-31 | $91.66 Million | +507.03% |
| 2019-12-31 | $15.10 Million | +37.87% |
| 2018-12-31 | $10.95 Million | +126.80% |
| 2017-12-31 | $4.83 Million | -66.29% |
| 2016-12-31 | $14.32 Million | +21.78% |
| 2015-12-31 | $11.76 Million | +14.79% |
| 2014-12-31 | $10.25 Million | +75.34% |
| 2013-12-31 | $5.84 Million | +179.22% |
| 2012-12-31 | $2.09 Million | +174.67% |
| 2011-12-31 | $762.00K | -- |
About Tempest Therapeutics Inc
Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma that completed Phase 2 clinical trial; and TPST-14… Read more